The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Donepezil for dementia due to Alzheimer's disease
Abstract
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors. OBJECTIVES: The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due to Alzheimer's disease. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched using the terms 'donepezil', 'E2020' and 'Aricept' on 12 June 2005. This Register contains up-to-date records of all major health care databases and many ongoing trial databases. Members of the Donepezil Study Group and Eisai Inc were contacted. SELECTION CRITERIA: All unconfounded, double-blind, randomized controlled trials in which treatment with donepezil was compared with placebo for patients with mild, moderate or severe dementia due to Alzheimer's disease. DATA COLLECTION AND ANALYSIS: Data were extracted by one reviewer (JSB), pooled where appropriate and possible, and the pooled treatment effects, or the risks and benefits of treatment estimated. MAIN RESULTS: 23 trials are included, involving 5272 participants. Most trials were of 6 months or less duration in selected patients. Available outcome data cover domains including cognitive function, activities of daily living, behaviour , global clinical state and health care resource costs. For cognition there is a statistically significant improvement for both 5 and 10 mg/day of donepezil at 24 weeks compared with placebo on the ADAS-Cog scale (-2.01 points MD, 95%CI -2.69 to -1.34, p<0.00001); -2.80 points, MD 95% CI -3.74 to -2.10, p<0.00001) and for 10 mg/day donepezil compared with placebo at 52 weeks (1.84 MMSE points, 95% CI, 0.53 to 3.15, p=0.006). The results show some improvement in global clinical state (assessed by a clinician) in people treated with 5 and 10 mg/day of donepezil compared with placebo at 24 weeks for the number of patients showing improvement or no change (OR 2.18, 95% CI 1.53 to 3.11, p=<0.0001, OR 2.38, 95% CI 1.78 to 3.19, p<0.00001). Benefits of treatment were also seen on measures of activities of daily living and behaviour, but not on the quality of life score . There were significantly more withdrawals before the end of treatment from the 10 mg/day (but not the 5 mg/day) donepezil group compared with placebo which may have resulted in some overestimation of beneficial changes at 10 mg/day. Benefits on the 10 mg/day dose were marginally larger than on the 5 mg/day dose. Two studies presented results for health resource use, and the associated costs. There were no significant differences between treatment and placebo for any item, the cost of any item, and for the total costs, and total costs including the informal carer costs. A variety of adverse effects were recorded, with more incidents of nausea, vomiting, diarrhoea, muscle cramps, dizziness, fatigue and anorexia (significant risk associated with treatment) in the 10 mg/day group compared with placebo but very few patients left a trial as a direct result of the intervention. AUTHORS' CONCLUSIONS: People with mild, moderate or severe dementia due to Alzheimer's disease treated for periods of 12, 24 or 52 weeks with donepezil experienced benefits in cognitive function, activities of daily living and behaviour. Study clinicians rated global clinical state more positively in treated patients, and measured less decline in measures of global disease severity. There is some evidence that use of donepezil is neither more nor less expensive compared with placebo when assessing total health care resource costs. Benefits on the 10 mg/day dose were marginally larger than on the 5 mg/day dose. Taking into consideration the better tolerability of the 5 mg/day donepezil compared with the 10 mg/day dose, together with the lower cost, the lower dose may be the better option. The debate on whether donepezil is effective continues despite the evidence of efficacy from the clinical studies because the treatment effects are small and are not always apparent in practice .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Donepezil application significantly improved the daily activities, behavior, and cognitive function of AD patients.427”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [427]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
(1988) · NFER-Nelson eBooks · Cited by 5,560
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Gélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 727
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 601
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.-J., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 580
BUCKS, R. S., ASHWORTH, D. L., WILCOCK, G. K., & SIEGFRIED, K. (1996) · Age and Ageing · doi:10.1093/ageing/25.2.113 · Cited by 579
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 503
Winblad, B., Kilander, L., Eriksson, S., Minthon, L., Båtsman, S., Wetterholm, A.-L., Jansson-Blixt, C., & Haglund, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68350-5 · Cited by 388
Tariot, P. N., Cummings, J. L., Katz, I. R., Mintzer, J., Perdomo, C. A., Schwam, E. M., & Whalen, E. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.t01-1-49266.x · Cited by 370
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., Pandita-Gunawardena, N. D., Hogg, F., Clare, C., & Damms, J. (2004) · Neurology · doi:10.1212/01.wnl.0000129990.32253.7b · Cited by 339
Severe Impairment Battery: A Neuropsychological Test for Severely Demented Patients
Panisset, M. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540130067012 · Cited by 323
Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V., & Ieni, J. R. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51306.x · Cited by 313
Rogers, S. L., & Friedhoff, L. T. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00079-5 · Cited by 292
Krishnan, K. R. R., Charles, H. C., Doraiswamy, P. M., Mintzer, J., Weisler, R., Yu, X., Perdomo, C., Ieni, J. R., & Rogers, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.2003 · Cited by 282
A new rating scale for dementia syndromes
Gottfries, C.-G., Bråne, G., Gullberg, B., & Steen, G. (1982) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(82)90031-0 · Cited by 280
Rogers, S. L., Doody, R. S., Pratt, R. D., & Ieni, J. R. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00067-5 · Cited by 265
Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial
Seltzer, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1852 · Cited by 257
CAMDEX, the cambridge examination for mental disorders of the elderly
Derix, M. M. A., & Walstra, G. J. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90064-6 · Cited by 239
The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease
Mega, M. S., Masterman, D. M., O'Connor, S. M., Barclay, T. R., & Cummings, J. L. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1388 · Cited by 236
BROOKER, C. (1998) · Journal of Psychiatric and Mental Health Nursing · doi:10.1046/j.1365-2850.1998.5605652.x · Cited by 229
Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer’s Disease
Gauthier, S., Feldman, H., Hecker, J., Vellas, B., Ames, D., Subbiah, P., Whalen, E., & Emir, B. (2002) · International Psychogeriatrics · doi:10.1017/s104161020200858x · Cited by 229
A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease
Wilcock, G., Howe, I., Coles, H., Lilienfeld, S., Truyen, L., Zhu, Y., & Bullock, R. (2003) · Drugs & Aging · doi:10.2165/00002512-200320100-00006 · Cited by 215
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Emir, B., Mastey, V., Subbiah, P., & The Donepezil MSAD Study Investigators Group (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51260.x · Cited by 202
Measurement of quality-of-life changes in patients with Alzheimer's disease.
Dejong, R. N., Osterlund, O. W., & Roy, G. W. (1989) · PubMed · Cited by 186
Homma, A., Takeda, M., Imai, Y., Udaka, F., Hasegawa, K., Kameyama, M., & Nishimura, T. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017259 · Cited by 177
Donepezil Therapy in Clinical Practice: A Randomized Crossover Study
Greenberg, S. M., Tennis, M. K., Brown, L. B., Gomez-Isla, T., Hayden, D. L., Schoenfeld, D. A., Walsh, K. L., Corwin, C., Daffner, K. R., Friedman, P., et al. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.94 · Cited by 169
Tune, L. E., Tiseo, P. J., Ieni, J. R., Perdomo, C. A., Pratt, R. D., Votaw, J. R., Jewart, R. D., & Hoffman, J. M. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00007 · Cited by 140
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Xu, Y., Ieni, J. R., & Schwam, E. M. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1325 · Cited by 114
Wimo, A. B., Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wetterholm, A.-L., Mastey, V., Haglund, A., Zhang, R. H., et al. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066669 · Cited by 112
Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic
Matthews, H. P., Korbey, J., Wilkinson, D. G., & Rowden, J. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200008)15:8<713::aid-gps187>3.0.co;2-i · Cited by 109
Stewart, A., Phillips, R., & Dempsey, G. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199807)13:7<445::aid-gps794>3.0.co;2-e · Cited by 109
Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients
Nobili, F. M., Vitali, P., Canfora, M., Girtler, N. G., Leo, C. D., Mariani, G., Pupi, A., & Rodriguez, G. (2002) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00110-4 · Cited by 91
Quality of life, social indicators, and criteria of change.
Blau, T. H. (1977) · Professional Psychology · doi:10.1037/0735-7028.8.4.464 · Cited by 89
Gauthier, S. G., Feldman, H., Hecker, J. R., Vellas, B. J., Emir, B., Subbiah, P., & on Behalf of The Donepezil MSAD Study Investigators’ Group (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001029 · Cited by 86
Thomas, A., Iacono, D., Bonanni, L., D’Andreamatteo, G., & ONOFRJ, M. C. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200101000-00007 · Cited by 86
ONOFRJ, M. C., Thomas, A., Iacono, D., Luciano, A. L., & Iorio, A. D. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200309000-00008 · Cited by 86
Economic evaluation of donepezil in moderate to severe Alzheimer disease
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Hux, M., Xu, Y., Schwam, E. M., Shah, S., & Mastey, V. (2004) · Neurology · doi:10.1212/01.wnl.0000134663.79663.6e · Cited by 84
Borroni, B., Colciaghi, F., Pastorino, L., Pettenati, C., Cottini, E., Rozzini, L., Monastero, R., Lenzi, G. L., Cattabeni, F., Luca, M. D., et al. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.442 · Cited by 82
AD2000: donepezil in Alzheimer's disease
Schneider, L. S. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16533-1 · Cited by 79
Quantitative EEG Changes in Alzheimer Patients during Long-Term Donepezil Therapy
Rodriguez, G., Vitali, P., Leo, C. D., Carli, F. D., Girtler, N. G., & Nobili, F. M. (2002) · Neuropsychobiology · doi:10.1159/000063576 · Cited by 78
Effects of Donepezil on Emotional/Behavioral Symptoms in Alzheimer's Disease Patients
Weiner, M., Martin‐Cook, K., Foster, B. M., Saine, K. C., Fontaine, C. S., & Svetlik, D. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0705 · Cited by 74
The Relationship Between Donepezil and Behavioral Disturbances in Patients With Alzheimer's Disease
Cummings, J. L., Donohue, J. A., & Brooks, R. L. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200005000-00008 · Cited by 71
ONOFRJ, M. C., Thomas, A., Luciano, A. L., Iacono, D., Rollo, A. D., D’Andreamatteo, G., & Iorio, A. D. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200207000-00004 · Cited by 54
Kemp, P. M. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.11.1567 · Cited by 37
Galasko, D. R., Schmitt, F. A., Jin, S., Saxton, J. A., Bennett, D. A., Sano, M., & Ferris, S. H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82096-5 · Cited by 36
Donepezil in the treatment of Alzheimer's disease
Rocca, P., Cocuzza, E., Marchiaro, L., & Bogetto, F. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00283-4 · Cited by 30
Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial
Barak, Y., Bodner, E., Zemishlani, H., Mirecki, I., & Aizenberg, D. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00187-x · Cited by 30
Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents
Fuschillo, C., Pia, S. L., Campana, F., Pinto, A. V., & Simone, L. D. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00134-0 · Cited by 23
Cameron, I. D., Curran, S., Newton, P., Petty, D. R., & Wattis, J. P. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200010)15:10<887::aid-gps212>3.0.co;2-m · Cited by 22
Rogers, S. L., Perdomo, C. A., & Friedhoff, L. T. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)90701-e · Cited by 22
Mohs, R. C., Doody, R. S., Morris, J., Ieni, J. R., Rogers, S. L., Perdomo, C. A., & Pratt, R. D. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80460-x · Cited by 22
To: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
(2001) · Neurology · doi:10.1212/wnl.57.10.1942-a · Cited by 22
Berger, F., Sramko, C. A., Frölich, L., & Calabrese, P. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80494-0 · Cited by 19
Another Advertisement for Donepezil
Finucane, T. E. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52230_1.x · Cited by 19
Delay in Nursing Home Placement with Donepezil
Schneider, L. S. S., & Qizilbash, N. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52277_3.x · Cited by 16
Donepezil Delay to Nursing Home Placement Study is Flawed
Karlawish, J. H. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52230_3.x · Cited by 15
O1-05-05 Donepezil and vitamin E as treatments for mild cognitive impairment
Petersen, R. C., Grundman, M., Thomas, R., & Thal, L. J. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80064-2 · Cited by 15
Rogers, S. L., & Friedhoff, L. T. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)88830-x · Cited by 13
Hegerl, U., Mergl, R., Henkel, V., Gallinat, J., Kotter, G., Muller-Siecheneder, F., Pogarell, O. M., Juckel, G., Schröter, A., Bahra, R., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00020 · Cited by 11
Wimo, A. B., Winblad, B. G., Mastey, V., Hertzman, P., Haglund, A., Miceli, R., Jacobson, L., & Subbiah, P. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82504-x · Cited by 9
5-12-21 Donepezil provides long-term clinical benefits for patients with Alzheimer's disease (AD)
Rogers, S. L., & Friedhoff, L. T. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)86335-6 · Cited by 9
Hecker, J. R., Gauthier, S. G., Vellas, B. J., Subbiah, P., & Whalen, E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82066-7 · Cited by 9
Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Winblad, B. G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., & Subbiah, P. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80492-7 · Cited by 8
Steinman, M. A., & Covinsky, K. E. (2003) · Journal of the American Geriatrics Society · doi:10.1034/j.1601-5215.2002.51022.x · Cited by 8
Donepezil provides long-term clinical benefits for patients with Alzheimer's disease
Pratt, R. D., Gauthier, S. G., Burns, A. S., & Perdomo, C. A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82652-4 · Cited by 8
Treatment of dementia patients with psychotic and behavioural symptoms with quetiapine and donepezil
Parsa, M. A., Poggi, E., & Barte, L. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80339-9 · Cited by 6
Gauthier, S. G., Feldman, H., Hecker, J. R., Vellas, B. J., Subbiah, P., & Whalen, E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82065-5 · Cited by 5
Sramko, C. A., Berger, F., Calabrese, P., & Frölich, L. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80493-9 · Cited by 5
McRae, T. D., Griesing, T., & Whalen, E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82644-5 · Cited by 5
Donepezil provides benefits in global function in moderate to severe Alzheimer's disease
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Subbiah, P., & Whalen, E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82641-x · Cited by 5
Panisset, M., Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Subbiah, P., & Whalen, E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82648-2 · Cited by 5
Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease
Luckmann, R., & Luckmann, R. (2002) · ACP Journal Club · doi:10.7326/acpjc-2002-136-2-059 · Cited by 5
Response to donepezil is not predicted by apolipoprotein E genotype and/or gender
Soininen, H. S., Winblad, B. G., Engedal, K., Waldemar, G., Wimo, A. B., Zhang, R. H., & Subbiah, P. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82062-x · Cited by 4
Donepezil treatment in patients with moderate to severe Alzheimer's disease reduces caregiver stress
Vellas, B. J., Feldman, H., Gauthier, S. G., Hecker, J. R., Subbiah, P., & Whalen, E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82647-0 · Cited by 4
Waldemar, G., Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Wimo, A. B., Zhang, R. H., & Subbiah, P. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83186-3 · Cited by 4
Brodaty, H., Bahra, R., Zhang, R., O'Leary, M., Short, K., & Barrington, M. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80490-3 · Cited by 4
Effects of donepezil on behaviour and other domains in moderate to severe Alzheimer's disease
Gauthier, S. G., Feldman, H., Hecker, J. R., Vellas, B. J., Subbiah, P., & Whalen, E. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80473-3 · Cited by 4
The clinical utility of donepezil: From randomized clinical trials to practice
Bullock, R. A., & Voss, S. E. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82083-7 · Cited by 3
P1-386 Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease
Shah, S. N., Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Hux, M., Xu, Y., Schwam, E. M., & Leaderer, M. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80698-5 · Cited by 3
O1-05-07 Behavioral benefits with continued donepezil treatment in Alzheimer's disease patients
Johannsen, P., Holub, R., Jakab, G., Jakobsen, S., Kalisvaart, K. J., Kozubski, W. P., Kurz, A., Triau, E., Tsolaki, M., Bergendorff, L., et al. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80066-6 · Cited by 3
Donepezil Italian global impact study (DIGIS)
Tettamanti, M., Casilli, D., Baldinetti, F., Apollonio, I., Ruffo, P., Nobili, A., Riva, E., & Lucca, U. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83415-6 · Cited by 3
Froelich, L., Gertz, H.-J., Heun, R., Heuser, I., Jendroska, K., Kornhuber, J., Kurz, A., Müller‐Thomsen, T., Ries, F., Waechtler, C. H., et al. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80475-7 · Cited by 3
Schindler, R. J., Zhang, R., Ieni, J. R., & Li, H. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(04)80657-2 · Cited by 2
(2005) · Archives of Neurology · doi:10.1001/archneur.62.5.825 · Cited by 2
Cited by
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Self-citationKavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Metadata
- Authors
- Birks, J., & Harvey, R. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-01-25
- Issue
- 1
- Pages
- CD001190-CD001190
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W4211091205
- Cited by
- 285
- References
- 100
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.